Current thinking in the health care management of children with cerebral palsy

Graham, David; Paget, Simon P; Wimalasundera, Neil

doi:10.5694/mja2.12106

ARTICLE
AUTHORS
REFERENCES

Topics

Pediatric medicine

Nervous system diseases

Summary

Cerebral palsy is a developmental disorder of movement and posture which is often associated with comorbidities.
While there is currently a limited range of evidence‐based treatments that change the underlying pathology of cerebral palsy, there are many areas in which health care professionals can change the natural history of cerebral palsy and improve participation and quality of life for children with this condition.
Early identification has become of paramount importance in the management of cerebral palsy, and it is hoped that it will allow earlier access to cerebral palsy interventions that may improve the natural history of the condition.
Common challenges in the management of cerebral palsy include spasticity and dystonia, management of pain, hip surveillance, sleep and feeding, swallowing and nutrition.
The six Fs framework (function, family, fitness, fun, friends and future) provides a guide to developing shared goals with families in the management of cerebral palsy.

1 Concord Centre for Mental Health, Sydney, NSW
2 Kids Neuroscience Centre, Kids Research, Sydney, NSW
3 Kids Rehab, Children's Hospital at Westmead, Sydney, NSW
4 Royal Children's Hospital Melbourne, Melbourne, VIC

Correspondence: david.graham1@health.nsw.gov.au

Competing interests:

No relevant disclosures.

1. Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy — April 2006. Dev Med Child Neurol 2007; 49: 8–14.
2. Reddihough D. Cerebral palsy in childhood. Aust Fam Physician 2011; 40: 192–196.
3. Australian Cerebral Palsy Register. Australian Cerebral Palsy Register Report 2016. ACPR; 2016. https://www.cpregister.com/pubs/pdf/ACPR-Report_Web_2016.pdf (viewed Sept 2017).
4. Jacobsson B, Hagberg G. Antenatal risk factors for cerebral palsy. Best Pract Res Clin Ob 2004; 18: 425–436.
5. Reid SM, Meehan E, McIntyre S, et al. Temporal trends in cerebral palsy by impairment severity and birth gestation. Dev Med Child Neurol 2016; 58(Suppl 2): 25–35.
6. Oddie S, Tuffnell DJ, McGuire W. Antenatal magnesium sulfate: neuro‐protection for preterm infants. Arch Dis Child Fetal Neonatal Ed 2015; 100: F553–F557.
7. Barrington KJ. The adverse neuro‐developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatrics 2001; 1: 1.
8. Ellenberg JH, Nelson KB. The association of cerebral palsy with birth asphyxia: a definitional quagmire. Dev Med Child Neurol 2013; 55: 210–216.
9. Jacobs SE, Berg M, Hunt R, et al. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database System Rev 2013; (1): CD003311.
10. Graham HK, Rosenbaum P, Paneth N, et al. Cerebral palsy. Nat Rev Dis Primers 2016; 2: e15082.
11. Fahey M, Maclennan A, Kretzschmar D, et al. The genetic basis of cerebral palsy. Dev Med Child Neurol 2017; 59: 462–469.
12. McMichael G, Girirajan S, Moreno‐De‐Luca A, et al. Rare copy number variation in cerebral palsy. Eur J Hum Genet 2014; 22: 40–45.
13. Novak I, Morgan C, Adde L, et al. Early, accurate diagnosis and early intervention in cerebral palsy: advances in diagnosis and treatment. JAMA Pediatr 2017; 171: 897–907.
14. Herskind A, Greisen G, Nielsen JB. Early identification and intervention in cerebral palsy. Dev Med Child Neurol 2015; 57: 29–36.
15. Spittle AJ, Olsen J, Kwong A, et al. The Baby Moves prospective cohort study protocol: using a smartphone application with the General Movements Assessment to predict neurodevelopment outcomes at age 2 years for extremely preterm or extremely low birthweight infants. BMJ Open 2016; 6: e013446.
16. Maitre NL, Chorna O, Romeo DM, Guzzetta A. Implementation of the Hammersmith Infant Neurological Examination in a high‐risk infant follow‐up program. Paediatr Neurol 2016; 65: 31–38.
17. Morgan C, Darrah J, Gordon AM, et al. Effectiveness of motor interventions in infants with cerebral palsy: a systematic review. Dev Med Child Neurol 2016; 58: 900–909.
18. Ashwal S, Russman BS, Blasco PA, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurol 2004; 62: 851–863.
19. National Institute for Health and Care Excellence. Cerebral palsy in under 25s: assessment and management [website]. NICE guideline NG62. NICE; 2017. https://www.nice.org.uk/guidance/ng62 (viewed Nov 2017).
20. Bax M, Tydeman C, Flodmark O. Clinical and MRI correlates of cerebral palsy: the European Cerebral Palsy Study. JAMA 2006; 296: 1602–1608.
21. Bleyenhuft Y, Ebner‐Karestinos D, Surana B, et al. Intensive upper‐ and lower‐extremity training for children with bilateral cerebral palsy: a quasi‐randomized trial. Dev Med Child Neurol 2017; 59: 625–633.
22. Morgan C, Novak I, Dale RC, et al. Single blind randomised controlled trial of GAME (goals – activity – motor enrichment) in infants at high risk of cerebral palsy. Res Dev Disabil 2016; 55: 256–267.
23. Boyd RN, Ziviani J, Sakewski L, et al. REACH: study protocol of a randomized trial of rehabilitation very early in congenital hemiplegia. BMJ Open 2017; 7: e017204ba.
24. Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000; 42: 816–824.
25. Sanger TD, Chen D, Fehlings DL, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25: 1538–1549.
26. Sanger TD, Chen D, Delgado MR, et al; Taskforce on Childhood Motor Disorders. Definition and classification of negative motor signs in childhood. Pediatrics 2006, 118: 2159–2167.
27. Sanger TD, Delgado MR, Gaebler‐Spira D, et al; Taskforce on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111: e89–e97.
28. Rice J, Skuza P, Baker F, et al. Identification and measurement of dystonia in cerebral palsy. Dev Med Child Neurol 2017; 59: 1249–1255.
29. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997; 39: 214–223.
30. World Health Organization. International classification of functioning, disability and health — children and youth version. Geneva: WHO; 2007. http://apps.who.int/iris/bitstream/handle/10665/43737/9789241547321_eng.pdf;jsessionid=1B7636E738A4675BE864CDBD413431E2?sequence=1 (viewed Nov 2017).
31. Rosenbaum P, Gorter JW. The “F‐words” in childhood disability: I swear this is how we should think!. Child Care Health Dev 2012; 38: 457–463.
32. Novak I, McIntyre S, Morgan C, et al. A systematic review of interventions for children with cerebral palsy: state of the evidence. Dev Med Child Neurol 2013; 55: 885–910.
33. Liow NYK, Gimeno H, Lumsden DE, et al. Gabapentin can significantly improve dystonia severity and quality of life in children. Eur J Paediatr Neurol 2015; 20: 100–107.
34. Sayer C, Lumsden De, Kaminska M, Lin JP. Clonidine use in the outpatient management of severe secondary dystonia. Eur J Paediatr Neurol 2017; 21: 621–626.
35. Koy A, Hellmich M, Pauls KA, et al. Effects of deep brain stimulation in dyskinetic cerebral palsy: a meta‐analysis. Mov Disord 2013; 28: 647–654.
36. Lumsden DE, Kaminska M, Gimeno H, et al. Proportion of life lived with dystonia inversely correlates with response to pallidal deep brain stimulation in both primary and secondary childhood dystonia. Dev Med Child Neurol 2013; 55: 567–574.
37. Aquilina K, Graham D, Wimalasundera N. Selective dorsal rhizotomy: an old technique re‐emerging. Arch Dis Child 2015; 100: 798–802.
38. Hasnat MJ, Rice JE. Intrathecal baclofen for treating spasticity in children with cerebral palsy. Cochrane Database Syst Rev 2015; (11): CD004552.
39. Soo B, Howard JJ, Boyd RN, et al. Hip displacement in cerebral palsy. J Bone Joint Surg Am 2006; 88: 121–129.
40. Wynter M, Gibson N, Kentish M, et al. Australian hip surveillance guidelines for children with cerebral palsy 2014 [website]. Australasian Academy of Cerebral Palsy and Developmental Medicine; 2014. https://www.ausacpdm.org.au/resources/australian-hip-surveillance-guidelines (viewed Nov 2017).
41. Novak I, Hines M, Goldsmith S, Barclay R. Clinical prognostic messages from a systematic review on cerebral palsy. Pediatrics 2012; 130: e1285–e1312.
42. Penner M, Xie W, Binepal N, et al. Characteristics of pain in children and youth with cerebral palsy. Pediatrics 2013; 132: e407–e413.
43. Dang VM, Colver A, Dickinson HO, et al. Predictors of participation of adolescents with cerebral palsy: a European multi‐centre longitudinal study. Res Dev Disabil 2014; 36C: 551–564.
44. Kingsnorth S, Orava T, Provvidenza C, et al. Chronic pain assessment tools for cerebral palsy: a systematic review. Pediatrics 2015; 136: e947–e960.
45. Pin TW, Elmasry J, Lewis J. Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: a systematic review. Dev Med Child Neurol 2013; 55: 304–313.
46. Beecham E, Candy B, Howard R, et al. Pharmacological interventions for pain in children and adolescents with life‐limiting conditions. Cochrane Database Syst Rev 2015; (3): CD010750.
47. Dahlseng MO, Andersen GL, da Graca Andrada M, et al; Surveillance of Cerebral Palsy in Europe Network. Gastrostomy tube feeding of children with cerebral palsy: variation across six European countries. Dev Med Child Neurol 2012; 54: 938–944.
48. Reid SM, Johnson HM, Reddihough DS. The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities. Dev Med Child Neurol 2010; 52: e23–e28.
49. Parr JR, Todhunter E, Pennington L, et al. The Drooling Reduction Intervention (DRI) trial: is hyoscine or glycopyrronium more effective and acceptable for the treatment of drooling in children with neurodisability? Arch Dis Child 2016; 101: A55–A56.
50. Henderson RC, Lark RK, Gurka MJ, et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002; 110: e5.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Current thinking in the health care management of children with cerebral palsy

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *